Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Donepezil for the treatment of agitation in Alzheimer's disease.

Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group..

N Engl J Med. 2007 Oct 4;357(14):1382-92.

2.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
3.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group..

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
4.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

5.

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group..

Curr Med Res Opin. 2002;18(6):347-54.

PMID:
12442882
6.

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P.

N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668.

7.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

Prasher VP, Huxley A, Haque MS; Down syndrome Ageing Study Group..

Int J Geriatr Psychiatry. 2002 Mar;17(3):270-8.

PMID:
11921156
8.
9.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group..

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
10.

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm AL, Jansson-Blixt C, Haglund A; Severe Alzheimer's Disease Study Group..

Lancet. 2006 Apr 1;367(9516):1057-65. Erratum in: Lancet. 2006 Nov 11;368(9548):1650. Lancet. 2006 Jun 17;367(9527):1980.

PMID:
16581404
11.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group..

JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.

12.

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.

Cummings JL, McRae T, Zhang R; Donepezil-Sertraline Study Group..

Am J Geriatr Psychiatry. 2006 Jul;14(7):605-12.

PMID:
16816014
13.
14.

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P; AD2000 Collaborative Group..

Lancet. 2004 Jun 26;363(9427):2105-15.

PMID:
15220031
16.

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B; Donepezil MSAD Study Investigators Group..

Int Psychogeriatr. 2002 Dec;14(4):389-404.

PMID:
12670060
17.

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.

Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237-44.

PMID:
10325453
18.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
19.

Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.

Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Takase T, Ohbayashi T.

Dement Geriatr Cogn Disord. 2009;27(3):232-9. doi: 10.1159/000203887. Epub 2009 Feb 25.

PMID:
19246907
20.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group..

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

Supplemental Content

Support Center